Form 4: 4D Molecular Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc., sold 3,270 shares of common stock on August 13, 2026.
Summary
- Option exercise/conversion: acquired 1,635 Common Stock at $4.14 ($6,769) on August 13, 2026; holds 10,252 after (Direct).
- Open-market sale: disposed of 1,635 Common Stock at $12.00 ($19,620) on August 13, 2026; holds 8,617 after (Direct).
- Option exercise/conversion: acquired 1,635 Common Stock at $4.14 ($6,769) on August 17, 2026; holds 10,252 after (Direct).
- Open-market sale: disposed of 1,635 Common Stock at $12.20 ($19,947) on August 17, 2026; holds 8,617 after (Direct).
- Option exercise/conversion: disposed of 1,635 Stock Option (Right to Buy) on August 13, 2026; holds 61,336 after (Direct).
- Option exercise/conversion: disposed of 1,635 Stock Option (Right to Buy) on August 17, 2026; holds 59,701 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $39,567 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Scott Bizily — Officer (Chief Legal Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-13 | Option exercise/conversion | Common Stock | 1,635 | $4 | $6.8K | 10,252 |
| 2026-08-13 | Open-market sale | Common Stock | 1,635 | $12 | $19.6K | 8,617 |
| 2026-08-17 | Option exercise/conversion | Common Stock | 1,635 | $4 | $6.8K | 10,252 |
| 2026-08-17 | Open-market sale | Common Stock | 1,635 | $12 | $19.9K | 8,617 |
| 2026-08-13 | Option exercise/conversion | Stock Option (Right to Buy) | 1,635 | — | — | 61,336 |
| 2026-08-17 | Option exercise/conversion | Stock Option (Right to Buy) | 1,635 | — | — | 59,701 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-13 | Option exercise/conversion (1,635 shares) |
| 2026-08-13 | Open-market sale (1,635 shares) |
| 2026-08-17 | Option exercise/conversion (1,635 shares) |
| 2026-08-17 | Open-market sale (1,635 shares) |
| 2026-08-13 | Option exercise/conversion (1,635 shares) |
| 2026-08-17 | Option exercise/conversion (1,635 shares) |
Keywords
insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, Scott Bizily
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.